Loading…
NuCana plc is projected to rise to $2.31 by 2027, a +7% move from its current price of $2.15. NCNA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.06 | $2.15 | $2.25 | +0.04% |
| May 30 | $2.02 | $2.15 | $2.29 | +0.08% |
| May 31 | $2.00 | $2.15 | $2.32 | +0.12% |
| Jun 1 | $1.98 | $2.15 | $2.35 | +0.16% |
| Jun 2 | $1.96 | $2.15 | $2.37 | +0.20% |
| Jun 3 | $1.94 | $2.16 | $2.40 | +0.24% |
| Jun 4 | $1.92 | $2.16 | $2.42 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.92 | $2.16 | $2.42 | +0.28% |
| Week 2 | $1.84 | $2.16 | $2.54 | +0.56% |
| Week 3 | $1.78 | $2.17 | $2.64 | +0.84% |
| Week 4 | $1.73 | $2.17 | $2.73 | +1.13% |
| Week 5 | $1.69 | $2.18 | $2.82 | +1.41% |
| Week 6 | $1.65 | $2.19 | $2.89 | +1.70% |
| Week 7 | $1.62 | $2.19 | $2.97 | +1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NuCana plc is a clinical-stage biopharmaceutical company focused on developing medicines to treat cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines, with the aim of overcoming the limitations of nucleoside analogs and generating concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer.
It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
NuCana plc (NCNA) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on cancer therapies. The current price is $2.02 and the market capitalization is $8.41M, with a market rank of 5202. The stock sits within a broader price outlook that shows a progression of estimates through 2030 and beyond."
A major floor 37.7% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 6.5% above — a clean break opens room to run.
A major ceiling 54.0% above — clearing it would confirm fresh momentum.
Key NCNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NCNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.05 | Buy | $2.06 | Buy |
| MA 10 | $2.03 | Buy | $2.05 | Buy |
| MA 20 | $2.07 | Buy | $2.05 | Buy |
| MA 50 | $1.95 | Buy | $2.09 | Buy |
| MA 100 | $2.27 | Sell | $3.55 | Sell |
| MA 200 | $3.12 | Sell | $34.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.96 | Neutral |
| Stoch RSI (14) | 96.78 | Sell |
| CCI (20) | 60.34 | Neutral |
| Williams %R (14) | -9.37 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 1.90 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 90.63 | Sell |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 47.42 | Neutral |
| Momentum (10) | 0.29 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 2.05 | Buy |
| ADX (14) | 10.17 | Neutral |
| ATR (14) | 0.08 | Info |
Technically, the near-term picture is neutral. The RSI(14) is 50, and the stock trades around the key moving averages, with SMA50 at $1.94 and SMA200 at $3.17. The 30-day range stretches from $1.53 to $2.67, providing a cushion near support at $1.86 and resistance at $2.29.
The stock carries an annualized volatility of 80%, reflecting heightened price movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.34 | $2.15 | $2.42 | 0% | Neutral | |
| $1.73 | $2.31 | $3.32 | +7% | Neutral | |
| $1.87 | $2.61 | $3.96 | +21% | Bullish | |
| $1.86 | $2.71 | $4.28 | +26% | Bullish | |
| $1.93 | $2.91 | $4.76 | +36% | Bullish | |
| $1.71 | $2.66 | $4.47 | +24% | Bullish | |
| $1.61 | $2.59 | $4.47 | +21% | Bullish | |
| $1.53 | $2.53 | $4.47 | +18% | Neutral | |
| $1.51 | $2.57 | $4.65 | +20% | Neutral | |
| $1.98 | $3.46 | $6.37 | +61% | Bullish | |
| $1.80 | $3.58 | $7.17 | +67% | Bullish | |
| $3.16 | $7.01 | $15.79 | +226% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.34 | $2.15 | $2.55 | +0.00% |
| June 2026 | $1.90 | $2.26 | $2.77 | +4.96% |
| July 2026 | $1.85 | $2.23 | $2.79 | -1.19% |
| August 2026 | $1.68 | $2.05 | $2.61 | -8.03% |
| September 2026 | $1.63 | $2.00 | $2.58 | -2.45% |
| October 2026 | $1.63 | $2.02 | $2.64 | +1.13% |
| November 2026 | $1.53 | $1.91 | $2.51 | -5.68% |
| December 2026 | $1.45 | $1.82 | $2.42 | -4.80% |
Click any year to see its month-by-month NCNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NCNA could reach as high as $2.42, with a base case around $2.15 and support toward $1.34 — roughly 0% from $2.15. A consolidation phase looks the most probable path here.
Expect NCNA to range from $1.73 to $3.32 through 2027. The $2.31 average target implies a +7% move from current prices. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
The NCNA price prediction for 2028 points to an average of $2.61 (low $1.87, high $3.96) — a potential gain of +21% on today's $2.15. Buyers look set to stay in control over this stretch.
In 2029, NCNA is projected to trade between $1.86 and $4.28, averaging $2.71 — a potential gain of +26% from today's $2.15. That is up +4% on the projected 2028 average. Momentum favours further upside here.
NuCana plc's 2030 outlook centres on $2.91, within a $1.93 to $4.76 range. That is up +7% on the projected 2029 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, NCNA could reach as high as $4.47, with a base case around $2.66 and support toward $1.71 — roughly +24% from $2.15. Momentum favours further upside here.
Expect NCNA to range from $1.61 to $4.47 through 2032. The $2.59 average target implies a +21% move from current prices. That is -2% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The NCNA price prediction for 2033 points to an average of $2.53 (low $1.53, high $4.47) — a potential gain of +18% on today's $2.15. Price action looks broadly range-bound.
In 2034, NCNA is projected to trade between $1.51 and $4.65, averaging $2.57 — a potential gain of +20% from today's $2.15. That is up +2% on the projected 2033 average. A consolidation phase looks the most probable path here.
NuCana plc's 2035 outlook centres on $3.46, within a $1.98 to $6.37 range. That is up +34% on the projected 2034 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2040, NCNA could reach as high as $7.17, with a base case around $3.58 and support toward $1.80 — roughly +67% from $2.15. Buyers look set to stay in control over this stretch.
Expect NCNA to range from $3.16 to $15.79 through 2050. The $7.01 average target implies a +226% move from current prices. That is up +96% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NCNA today (≈ 465.116279 NCNA) could be worth
$3,261.07
+$2,261.07 (+226%) by 2050 · US Dollar
Based on the average projected NCNA price of $7.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NCNAwould be worth at today's price.
$1,000 invested in NCNA on May 27, 2025 (≈ 128.205125 NCNA) would be worth
$275.64
-$724.36 (-72.4%) today · 0.28× · US Dollar
Based on a NCNA entry price of $7.8 vs. today's $2.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.04 | $1,053.92 | +5.4% |
| 1 month ago | $2.21 | $972.85 | -2.7% |
| 3 months ago | $2.19 | $981.74 | -1.8% |
| 6 months ago | $4.28 | $502.34 | -49.8% |
| 1 year ago | $7.8 | $275.64 | -72.4% |
| All time (5.0y) ago | $13,500 | $0.16 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NCNA forecast.
Our base-case forecast reaches $4.30 around 2050.
Implied market cap at $4.30: $17.9M
The multi-year forecast shows a rise in average price and positive ROI across several years, with clear milestones by year. For 2026 the avg is $2.02 with an ROI of 0% and a NEUTRAL sentiment. By 2027 the avg is $2.19 with an ROI of 8.4% (NEUTRAL), and 2028 is $2.43 with 20.5% (BULLISH).
In 2029 the avg is $2.54 with 25.7% ROI (BULLISH). The 2030 forecast reaches an avg of $2.75 with a 36% ROI (BULLISH). The trend continues through 2031–2034 with 2031 at $2.48 (22.7%), 2032 at $2.43 (20.5%), 2033 at $2.40 (18.7%), and 2034 at $2.41 (19.3%).
The 2035 forecast shows a stronger gain with an avg of $3.26 and 61.4% ROI (BULLISH); by 2040 the avg is $3.32 with 64.6% ROI (BULLISH). The long-range view culminates in 2050 with an avg of $6.62, a max of $14.76, and a 227.7% ROI (BULLISH). These figures illustrate a generally bullish trajectory over time, though they are estimates and not guarantees, and there are inherent risks and uncertainties.
Tap a question to reveal the answer.
In 2030, the avg price is forecast at $2.75 with a 36% ROI and a BULLISH sentiment.
The forecast shows positive ROI in multiple years, including 2028 (20.5%), 2029 (25.7%), 2030 (36%), and 2050 (227.7%), but these are estimates and not guarantees.
Yes, the 2050 forecast lists a max of $14.76 with an avg of $6.62 and a 227.7% ROI (BULLISH).
Current price is $2.02 and market cap is $8.41M.
RSI(14) is 50, SMA50 is $1.94, SMA200 is $3.17, with support at $1.86 and resistance at $2.29. The 30-day range is $1.53 to $2.67, sentiment is NEUTRAL, and annualized volatility is 80%.
NuCana plc Community Discussion
0Share your NuCana plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.